Sangamo Therapeutics: More Catalysts Powering A Gene-Based Innovator

The Federal Trade Commission staff reviewing Roche's plan to buy U.S.-based gene therapy specialist Spark Therapeutics for $4.3 billion recommended that the deal be approved without requiring any asset sales, the Capitol Forum reported on Thursday......»»

Sangamo Therapeutics made a handy gain to start out the week after the firm, in conjunction with Pfizer, announced updated results from a mid-stage trial evaluating a treatment for hemophilia......»»

Biotech giant Vertex Pharmaceuticals announced plans Thursday to acquire a Cambridge-based preclinical gene editing startup, giving a run for the money to fellow Cambridge drugmaker Sarepta Therapeutics and others developers of drugs for Duchenne m.....»»

Gainers Sangamo Therapeutics Inc (NASDAQ: SGMO) shares climbed 35.1 percent to $12.87 after the company announced positive Phase 1/2 interim data for its investigational Hemophilia gene therapy. read more.....»»

Which of these gene editing stocks will come out on top?.....»»

Cambridge startup CRISPR Therapeutics and Boston-based Vertex Pharmaceuticals said on Wednesday that the FDA has put on hold a highly anticipated upcoming trial of their experimental gene editing drug for sickle cell disease. CRISPR (Nasdaq: CRIS.....»»

Gene Editing Is Coming: Get In Front Of Sangamo Therapeutics"s "Irrational Extrapolation Event".....»»

Sangamo Therapeutics Inc (NASDAQ: SGMO) announced Monday it would acquire TxCell for about €72 million to complement its ex vivo gene editing program. read more.....»»

Despite a second-quarter earnings loss, Audentes Therapeutics, Inc. (NASDAQ: BOLD)’s existing catalysts are reason enough for a bullish stance, according to Mizuho.  Latest R.....»»

Investor optimism is picking up ahead of important gene-editing trial data in September......»»

Sangamo Therapeutics Inc. shares dropped 13% in Wednesday premarket trade after the company released results for a phase 1/2 trial of its gene editing candidate SB-913, which is intended for the .....»»

Sangamo Therapeutics Inc (NASDAQ: SGMO) shares opened sharply lower Wednesday following the release of clinical trial data for its pipeline candidate SB-913. read more.....»»

The trial marked the first instance of gene editing, or adding a new copy of a gene into the DNA of a patient’s cells, completed inside the body......»»

The trial marked the first instance of gene editing, or adding a new copy of a gene into the DNA of a patient’s cells, completed inside the body......»»

Investors got more disappointing news regarding Sangamo Therapeutics' gene-editing approach this week......»»

Roche Holding AG is to buy U.S.-based Spark Therapeutics in a $4.3 billion deal that will give the Swiss drugmaker a foothold in gene therapy. Ciara Lee reports......»»

In another boost to Philadelphia’s standing as a cell and gene therapy hub, Cranbury, New Jersey-based Amicus Therapeutics said Tuesday it is establishing a new global research and gene therapy center at uCity Square, where the company expects t.....»»

Top analyst Gene Munster thinks Apple's OpenAI partnership will deliver the "biggest upgrade" in Siri's history. Latest R.....»»

In this week’s Petri Dish we’ll take a look at a new Cambridge company founded by gene-editing experts that emerged with some big funding, as well as Foghorn Therapeutics’ new CFO and the awardees of $2.8 million in women's health funding......»»

Chef Aaron Adams unveils latest plant-based restaurant, a pop-up at Langbaan, and Gene Simmons' Rock & Brews lands in Clark County......»»